Posted on May 10th, 2022. Posted by ICR Westwicke
The Walt Disney Company and its CEO Bob Chapek are paying a high price for staying outside of politics, and then jumping into it. Disney’s entanglements with its employees on one side and Florida’s governor and lawmakers have spilled over with very real implications. Gov. Ron DeSantis has signed into law a bill that strips Disney of its special tax status in the state, a move which will effectively change how the company operates.
Continue Reading
Posted on April 14th, 2022. Posted by ICR Westwicke
For CEOs and company leaders, interacting with the media isn’t an option — it’s a necessity. The media plays a significant role in telling your company story and shaping your public image. To ensure they tell an accurate story, however, it’s essential to learn how to work with the media and strive to understand how the industry is shifting.
Continue Reading
Posted on March 28th, 2022. Posted by ICR Westwicke
Creating an investor relations strategy is no small task — but it’s a critical step for any public company. To meet the expectations of investors and analysts, company leaders must develop a strategic approach for messaging, earnings calls, guidance, conferences, investor interactions and more. While that can seem overwhelming, an effective IR process actually boils down to just seven essential elements. With a plan for each of these areas, you can build a quality, long-term shareholder base and enhance equity market value.
Continue Reading
Posted on February 21st, 2022. Posted by ICR Westwicke
Public healthcare companies often question the best course of action during quiet periods – those stretches of time during which they should limit their interaction with Wall Street due to their knowledge of material and timely information that has not yet been disclosed. Specifically, management teams struggle to figure out what the quiet period means for their investor relations (IR) efforts.
Continue Reading
Posted on February 9th, 2022. Posted by ICR Westwicke
If your company is publicly traded or a private company preparing for an IPO, then you likely have two separate communication tasks, one focused on reaching investors and financial analysts, the other on reaching customers and the general public – investor relations and public relations.
Continue Reading
Posted on February 4th, 2022. Posted by ICR Westwicke
The last year has been challenging for businesses — from global pandemic, economic uncertainty and supply chain disruptions to labor shortages and growing concern over inflation — but there was also robust activity in the financial markets, and in healthcare specifically. See what you missed in 2021 with our most-read posts of the year.
Continue Reading
Posted on January 12th, 2022. Posted by ICR Westwicke
The COVID-19 pandemic continues to drive significant changes to nearly every industry, from real estate to staffing to consumer goods — but it fundamentally changed how consumers view and access healthcare. As the U.S. continues to navigate the pandemic, alongside mixed economic data, supply chain challenges, and labor challenges, what lies ahead for the healthcare industry in 2022? Below, our experts offer their predictions.
Continue Reading
Posted on December 21st, 2021. Posted by ICR Westwicke
Investors know that biotech and biopharma companies in the early development stages can be risky investments. So finding the right investors that believe the rewards will outweigh the risks requires strategy.
Continue Reading
Posted on November 18th, 2021. Posted by ICR Westwicke
As public health officials discuss whether to call subsequent COVID-19 vaccinations “boosters,” fearing it gives the impression that previous inoculations weren’t effective—some preferred “third dose” or “final dose”—chalk it up to yet another debate about words and nomenclature related to the worst global pandemic in a century.
Continue Reading
Posted on November 1st, 2021. Posted by ICR Westwicke
In the face of a global pandemic, capital markets have (understandably) seen unprecedented behavior over the past two years. With vaccines, rapid testing, and medical research at center stage of every news outlet and publication, the biotech sector has been especially active. There have been major shifts in both buy- and sell-side activities, leaving many companies wondering how to best raise capital as the world finds its new normal. As young and emerging biotech companies look forward, there is growing concern about the current and future state of funding.
Continue Reading
